MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV) in a research report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Down 3.3 %

MNOV opened at $2.03 on Friday. MediciNova has a 12-month low of $1.12 and a 12-month high of $2.16. The stock has a market cap of $99.56 million, a price-to-earnings ratio of -11.82 and a beta of 0.72. The business has a 50 day moving average of $1.51 and a 200-day moving average of $1.43.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. As a group, analysts expect that MediciNova will post -0.23 earnings per share for the current year.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.